Hemoglobinopathy Market Size To Worth Over US$ 1,001.6 Million in Terms of Revenue by 2020 to 2027 | Industry Share, Trends, Growth, Demand | Finds CMI

Hemoglobinopathies are among the most common inherited diseases around the world. The conditions can be divided into two main groups: thalassemia syndromes and structural hemoglobin variants. α- and β-thalassemia are the main types of thalassemia and the main structural hemoglobin variants are HbS, HbE and HbC.

The global hemoglobinopathy market is estimated to account for US$ 523.4 Mn in terms of value in 2019 and is expected to reach US$ 1,001.6 Mn by the end of 2027.

Global Hemoglobinopathy Treatment Market

Hemoglobinopathy comprises a range of disorders, which occur due to altered structure of hemoglobin. Hemoglobin is present in the red blood cells that transports oxygen from the lung to the body. Hemoglobinopathy disorder are inherited and are passed on from one generation to another. It is further classified into two categories – 1. Thalassemia Syndrome 2. Structural Hemoglobin Variants. Thalassemia syndrome includes disorder related to synthesis defect. The synthesis defect of alpha globin gives rise to alpha thalassemia and defect in beta globin give rise to beta thalassemia. The structural hemoglobin variants occur due to alteration of alpha and beta chains that causes defect in structure.

Request sample copy: https://www.coherentmarketinsights.com/insight/request-sample/2801

Global Hemoglobinopathy Treatment Market Drivers

Increasing R&D activities are expected to support the global hemoglobinopathy treatment market growth over the forecast period. For instance, in September 2018, AstraZeneca initiated its clinical trial for Ticagrelor. It is being studied for the treatment of sickle cell disease. The drug is being studied for the evaluation of its safety and efficacy. Currently, it is undergoing the third phase of clinical trial.

Furthermore, in January 2019, Celgene Corporation and Acceleron Pharma Inc. started their clinical trial for luspatercept. It is being studied for the treatment of adult patients with beta-thalassemia. The drug is being tested for its safety, efficacy, and pharmacokinetics. In June 2019, the U.S. Food & Drug Administration (FDA) accepted biologics license application (BLA) of luspatercept. Hence, such developments are expected to drive the global hemoglobinopathy treatment market growth in the forthcoming years.

Furthermore, the key market players are indulged in obtaining approvals from regulatory bodies for their products, which is expected to impel the global hemoglobinopathy treatment market growth. For instance, June 2019, Bluebird Bio Inc. received the European Medicines Agency (EMA) approval for its product, Zynteglo. It is a gene therapy, which contains autologous CD34+ cells encoding βA-T87Q-globin gene. It is indicated for patients aged 12 years and above with transfusion-dependent β-thalassemia who do not have the β0/β0 genotype. Hence, such approvals are expected to impact the global hemoglobinopathy treatment market growth positively.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2801

However, disapprovals related to hemoglobinopathy treatment by regulatory bodies is expected to hamper the global hemoglobinopathy treatment market growth to a great extent. For instance, in May 2019, European Medical Agency (EMA) rejected an approval of a drug, Xyndari. Xyndari was manufactured by Emmaus Medical, Inc. It was being developed for the treatment of patients with sickle cell disease. Hence, this factor may have a negative impact on the global hemoglobinopathy treatment market development.

Global Hemoglobinopathy Treatment Market Regional Analysis

North America is expected to hold the leading position in the global hemoglobinopathy treatment market. Factors such as increase in prevalence of hemoglobinopathy disorders are expected to drive the global hemoglobinopathy treatment market growth. According to the data published by National Centre for Biotechnology Information (NCBI), in 2019, around 300,000 infants are born with sickle cell anemia annually and the population of sickle cell anemia in the U.S. was evaluated to be 100,000. Hence, higher prevalence of sickle cell anemia may increase the demand for treatment, thereby expected to support the global hemoglobinopathy treatment market growth.

Key Players

Some of the major players operating in the global hemoglobinopathy treatment market include Novartis AG, AstraZeneca, Bluebird Bio Inc., Bristol-Myers Squibb, Emmaus Medical, Inc., Acceleron Pharma, Inc., HemaQuest Pharmaceuticals Inc., Eli Lilly and Company, Celgene Corporation, and Acceleron Pharma, Inc.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/hemoglobinopathy-market-2939

Market Taxonomy

By Drug Type,

• Hydroxyurea
• Glutamine
• Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene)
• Luspatercept
• Others

By Disease Type,

• Sickle Cell Diseases
• Thalassemia
  • Alpha thalassemia
  • Beta Thalassemia
• Others

By Region,

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.